PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

Core Insights - PMGC Capital LLC plans to file a Schedule 13D with the U.S. Securities and Exchange Commission, disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. [1] - PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company's outstanding shares [2] - Alaunos Therapeutics is a clinical-stage oncology-focused cell therapy company exploring strategic alternatives, including mergers and acquisitions [3] Company Strategy - PMGC Capital believes Alaunos is undervalued and has significant potential to create shareholder value, intending to engage with Alaunos' management to explore strategic opportunities [4] - The company commends Alaunos Therapeutics for maintaining a clean capital structure and prudent financial stewardship during challenging market conditions [5] - PMGC Capital is focused on direct investments, strategic lending, and acquiring undervalued companies across diverse markets [6] Corporate Background - PMGC Holdings Inc. manages a diversified portfolio through strategic acquisitions and investments across various industries [7]